Osavampator

Chemical compound

Osavampator (developmental code names TAK-653 and NBI-1065845) is an experimental drug being investigated as a treatment for treatment-resistant depression. It is being developed by Neurocrine Biosciences and Takeda Pharmaceuticals (Millennium Pharmaceuticals, Inc.).

Nº Q116977443 ★

Commune · Savoirs

Osavampator

Chemical compound

Texte en anglais

Osavampator (developmental code names TAK-653 and NBI-1065845) is an experimental drug being investigated as a treatment for treatment-resistant depression. It is being developed by Neurocrine Biosciences and Takeda Pharmaceuticals (Millennium Pharmaceuticals, Inc.).

Sur Wikipédia

Texte en anglais Pas encore d'article dans ta langue : extrait en anglais.

Osavampator (developmental code names TAK-653 and NBI-1065845) is an experimental drug being investigated as a treatment for treatment-resistant depression. It is being developed by Neurocrine Biosciences and Takeda Pharmaceuticals (Millennium Pharmaceuticals, Inc.). Takeda Pharmaceuticals discovered the molecule originally, and holds exclusive right to market the drug in Japan, while Neurocrine Biosciences holds the right to market it to the rest of the world.

Texte : Wikipédia en anglais, CC BY-SA 4.0. · Image : User:Innerstream (Public domain) ·

Cartes voisines

Ouvrir

…

Confirmation